Abarbanel Mental Health Center — Biomedical Watch V2

Traitements1programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

1

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
RisperidoneBehavioral and psychological symptoms of dementia (BPSD) are among the most distressing manifestations of dementia. Pharmacotherapy is frequently used and especially in institutional settings. Current guidelines recommend the use of second-generation antipsychotics (SGAs). Nonetheless, there are concerns regarding both their safety and effectiveness in patients with dementia. Inconclusive evidence support the use of other psychoactive agents such as SSRI antidepressants or cognitive enhancers. In two published studies citalopram was as efficacious as, but better tolerated than perphenazine or risperidone in patients with BPSD. Thus, with proven efficacy and a beneficial safety profile the evaluation of the use of escitalopram for BPSD is warranted.	Alzheimer	Phase 4	Traitement symptomatique	Israel	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
escitalopram	Alzheimer	Phase 4	NCT01119638	EscBPSD — Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone	COMPLETED

Publications

2

Molécule	Indication / population	Titre	Journal	Date
Risperidone		Identification of EIF4A1 as a candidate molecular indicator of autism spectrum disorder using integrative bioinformatic and biological methods.	Brain research
Risperidone		Assessment of psychotropic medicines utilization patterns for the treatment of mental and neurological disorders in Public Hospitals of Hadiya Zone, Southern Ethiopia: A record-based study.	PLOS mental health